1. Development and Validation of a Risk Prediction Model of Linezolid-induced Thrombocytopenia in Elderly Patients
- Author
-
Li Yx, Chen Z, Gao S, Ye Y, Shen Y, Pan Mk, Lv Zq, and Qin Y
- Subjects
medicine.medical_specialty ,chemistry.chemical_compound ,Text mining ,chemistry ,business.industry ,Linezolid ,medicine ,Intensive care medicine ,business - Abstract
Background Linezolid is an oxazolidinone antimicrobial agent developed for treating multi-drug-resistant gram-positive bacterial infections. Objective This study aimed at investigating risk factors of linezolid (LI)-induced thrombocytopenia (LI-TP) and establishing a risk predictive model for LI-TP.Setting ZhongShan Hospital, FuDan University, China. Method A retrospective study was performed in patients aged ≥ 65 years receiving linezolid therapy from January 2015 to April 2021. Clinical characteristics and demographic data were collected and compared between patients with LI-TP and those without.Main outcome measures Incidence and risk factors of LI-TP in elderly patients.Results A total of 343 inpatients were included as the train set from January 2015 to August 2020. Among them, 67 (19.5%) developed LI-TP. Multivariate logistic regression analysis revealed that baseline platelet counts < 150×109·L-1 (OR=3.576; P< 0.001), age ≥ 75 years (OR=2.258; P=0.009), eGFR< 60 mL·(min·1.73m2)-1 (OR=2.553; P=0.002), duration of linezolid therapy ≥ 10 d (OR=3.218; PP=0.004), and concomitant with piperacillin-tazobactam (PTZ) (OR=3.863; P=0.006) were independent risk factors for LI-TP. The risk predictive model was established and exhibited a moderate discriminative power, with an AUC of 0.795 [95%CI 0.740-0.851] and 0.849 [95%CI 0.760-0.939] in train set (n=343) and validation set (n=90), respectively.Conclusion The risk factors of LI-TP in elderly patients were duration of linezolid therapy, age, eGFR, ICU admittance, baseline platelet counts, and concomitant with PTZ. A risk predictive model based on these risk factors may be useful to identify patients with high risk of LI-TP.
- Published
- 2021